Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
Original paper

Ethnic heterogeneity in steatosis-driven liver injury among MASLD patients: Han Chinese vs. Caucasian

Limin Lin
1
,
Junzhao Ye
1
,
Zhiyong Dong
2
,
Hong Deng
3
,
Yiyi Hu
4
,
Shiting Feng
1
,
Bing Liao
1
,
Xiaodong Zhuang
1
,
Bihui Zhong
1

  1. Sun Yat-sen University, the First Affiliated Hospital, China
  2. The First Affiliated Hospital of Jinan University, China
  3. Sun Yat-sen University, the Third Affiliated Hospital, China
  4. Shunde Hospital of Southern Medical University, China
Clin Exp HEPATOL 2025; 11, 3: 249–261
DOI: https://doi.org/10.5114/ceh.2025.154222
Online publish date: 2025/09/22
Article file
- Ethnic.pdf  [0.22 MB]
Get citation
 
PlumX metrics:
 
1. Byrne CD, Armandi A, Pellegrinelli V, et al. Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol 2025; 22: 314-328.
2. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
3. J Hepatol 2018; 69: 896-904.
4. Hagström H, Shang Y, Hegmar H, et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol 2024; 9: 944-956.
5. Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov 2025; 24: 171-189.
6. Lin L, Lai J, Luo L, et al. Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis. Ann Hepatol 2025; 30: 101780.
7. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-379.
8. Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: Comparison of prevalence and risk factors. Med Princ Pract 2011; 21: 56-62.
9. Tabibian JH, Lazo M, Durazo FA, et al. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol 2011; 26: 501-509.
10. Remigio-Baker RA, Allison MA, Forbang NI, et al. Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2017; 258: 89-96.
11. Rodriguez LA, Shiboski SC, Bradshaw PT, et al. Predicting non-alcoholic fatty liver disease for adults using practical clinical measures: Evidence from the multi-ethnic study of atherosclerosis. J Gen Intern Med 2021; 36: 2648-2655.
12. Noureddin M, Zelber-Sagi S, Wilkens LR, et al. Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: The multiethnic cohort. Hepatology 2020; 71: 1940-1952.
13. Palmer ND, Musani SK, Yerges-Armstrong LM, et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 2013; 58: 966-975.
14. Kallwitz ER, Guzman G, TenCate V, et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol 2009; 104: 64-69.
15. Bril F, Portillo-Sanchez P, Liu IC, et al. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. Diabetes Care 2018; 41: 187-192.
16. Rich NE, Noureddin M, Kanwal F, et al. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. Lancet Gastroenterol Hepatol 2021; 6: 422-424.
17. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542-1556.
18. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
19. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
20. Sperling LS, Mechanick JI, Neeland IJ, et al. The CardioMetabolic Health Alliance: Working toward a new care model for the metabolic syndrome. J Am Coll Cardiol 2015; 66: 1050-1067.
21. Dong Z, Luo Y, Zhang Z, et al. MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects. PLoS One 2014; 9: e111283.
22. Ye J, Wu Y, Li F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol 2019; 12: 1756284819879047.
23. Wilman HR, Kelly M, Garratt S, et al. Characterisation of liver fat in the UK Biobank cohort. PLoS One 2017; 12: e0172921.
24. Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol 2019; 29: 3564-3573.
25. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
26. Hagström H, Nasr P, Ekstedt M, et al. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand J Gastroenterol 2017; 52: 87-91.
27. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150-161.
28. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
29. Su GL, Sravanthi K, Huang R, et al. Metabolic abnormalities, liver and body fat in American versus Chinese patients with non-alcoholic fatty liver disease. JGH Open 2022; 6: 519-530.
30. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 2022; 18: 55-66.
31. Lim U, Monroe KR, Buchthal S, et al. Propensity for intra-abdominal and hepatic adiposity varies among ethnic groups. Gastroenterology 2019; 156: 966-75.e10.
32. Ciardullo S, Oltolini A, Cannistraci R, et al. Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. Am J Clin Nutr 2022; 115: 1528-1534.
33. Wulan SN, Schrauwen-Hinderling VB, Westerterp KR, et al. Liver fat accumulation in response to overfeeding with a high-fat diet: a comparison between South Asian and Caucasian men. Nutr Metab (Lond) 2015; 12: 18.
34. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
35. Wildman-Tobriner B, Middleton MM, Moylan CA, et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Gastroenterology 2018; 155: 1428-1435.e2.
36. Mohanty SR, Troy TN, Hu DZ, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804.
37. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-2224.
38. Jarasvaraparn C, Vilar-Gomez E, Yates KP, et al. Age, BMI, and type 2 diabetes modify the relationship between PNPLA3 and advanced fibrosis in children and adults with NAFLD. Clin Gastroenterol Hepatol 2024; 22: 1024-1036.e2.
39. Luukkonen PK, Porthan K, Ahlholm N, et al. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. Cell Metab 2023; 35: 1887-1896.e5.
40. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015; 35: 270-290.
41. Kalia HS, Gaglio PJ. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis 2016; 20: 215-224.
42. Cavalcante LN, Porto J, Mazo D, et al. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. Ann Hepatol 2022; 27: 100728.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.